Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

Teva Pharmaceutical Industries TEVA reported third-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks ...

Shares of Teva Pharmaceutical (NYSE:TEVA) gained in the premarket trading on Wednesday after the generic drugmaker reported better-than-expected Q3 2024 financials and raised its full-year outlook ...

The United States Department of Justice (DOJ) recently announced that Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. will pay $450 million to resolve allegations of violating the ...

was about creating a sustainable generics powerhouse,” Francis said in an interview with Fierce Pharma on Wednesday. “In no way were we in a sense stepping away from generics.” Teva said the ...

European Union antitrust authorities fined Israel’s Teva Pharmaceuticals TEVA1.92%increase; green up pointing triangle 462.6 million euros ($502.3 million), saying the company abused its market ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...

The EU on Thursday slapped the world's largest generic drugmaker Teva with a 462.6-million-euro ($502 million) fine for "abusing its dominant position" to impede competition for its blockbuster ...

Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by rival generic drugmakers, the company’s second major financial ...

BRUSSELS — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million ... The commission said the pharmaceutical firm “misused the patent system ...

Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust watchdog for thwarting fair competition by unfairly disparaging a rival ...

Oct. 31 (UPI) --The European Commission fined Teva Pharmaceuticals $503 million for delaying competition posed by rival generic drugmakers, the company's second major financial penalty this month.